Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The protein clusterin has been suggested to be involved in the pathogenesis of Alzheimer's disease (AD). Its expression is increased in brain regions affected by AD pathology, and to elucidate if there is a concomitant increase of clusterin also in the cerebrospinal fluid (CSF) in different neurological disorders, CSF samples from patients with AD, vascular dementia (VAD), Parkinson's disease (PD), and controls were analysed. Also longitudinal (five occasions) samples from patients with acute stroke were analysed, to follow any degenerative/regenerative phase after acute brain damage. However, there were no changes in CSF-clusterin levels from patients in AD, VAD, PD or acute stroke, as compared to controls. The increase of clusterin in brain tissue is suggested to reflect a regenerative response process, which here is shown not to be followed by a concomitant increase in the CSF. Thus, CSF-clusterin can not be used as an indicator or a diagnostic marker for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationNeuron numbers and dendritic extent in normal aging and Alzheimer’s disease
Coleman, P. D., & Flood, D. G. (1987) · Neurobiology of Aging · doi:10.1016/0197-4580(87)90127-8 · Cited by 772 · cited 1×
“The neuropathological changes associated with AD includes loss of neurones and their synapses [6,13], and an increased number of senile plaques (SP) and neurofibrillary tangles (NFT) compared to non-demented individuals of the same age [53].”
Oda, T., Wals, P., Osterburg, H. H., Johnson, S. A., Pasinetti, G. M., Morgan, T. E., Rozovsky, I., Stine, W. B., Snyder, S. W., Holzman, T. F., et al. (1995) · Experimental Neurology · doi:10.1006/exnr.1995.1080 · Cited by 352
May, P. C., Lampert-Etchells, M., Johnson, S. A., Poirier, J., Masters, J. N., & Finch, C. E. (1990) · Neuron · doi:10.1016/0896-6273(90)90342-d · Cited by 339 · cited 1×
“terin mRNA levels are reported [19,36,37], as well as”
BackgroundGhiso, J., Matsubara, E., Koudinov, A., Choi-Miura, N. H., Tomita, M., Wisniewski, T., & Frangione, B. (1993) · Biochemical Journal · doi:10.1042/bj2930027 · Cited by 304
Distribution of clusterin in Alzheimer brain tissue
McGeer, P. L., Kawamata, T., & Walker, D. G. (1992) · Brain Research · doi:10.1016/0006-8993(92)90071-g · Cited by 212 · cited 1×
“Antibodies to clusterin label SP [11,38,60] and NFT [38,60].”
BackgroundBertrand, P., Poirier, J., Oda, T., Finch, C. E., & Pasinetti, G. M. (1995) · Molecular Brain Research · doi:10.1016/0169-328x(95)00097-c · Cited by 210 · cited 4×
“increased levels of clusterin protein [4,32,41].”
BackgroundResultInfluentialSP-40,40 is a constituent of Alzheimer's amyloid
Choi-Miura, N. H., Ihara, Y., Fukuchi, K., Takeda, M., Nakano, Y., Tobe, T., & Tomita, M. (1992) · Acta Neuropathologica · doi:10.1007/bf00296787 · Cited by 158
Amyloid β binding proteins in vitro and in normal human cerebrospinal fluid
Golabek, A., Marques, M. A., Lalowski, M., & Wisniewski, T. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11565-7 · Cited by 99 · cited 1×
“Clusterin is also reported to be associated with soluble amyloid β [21,22, 33], and has thereby been proposed to have a protective role against amyloid β neurotoxicity [8,34].”
Tycko, B., Feng, L., Nguyen, L., Francis, A., Hays, A., Chung, W.-Y., Tang, M.-X., Stern, Y., Sahota, A., Hendrie, H., et al. (1996) · Human Genetics · doi:10.1007/s004390050234 · Cited by 61 · cited 2×
“Clinically, AD is characterised by progressive dementia with memory disturbances and instrumental symptoms [5,24,55].”
Cited by
Glial activation and inflammation along the Alzheimer’s disease continuum
Nordengen, K., Kirsebom, B.-E., Henjum, K., Selnes, P., Gísladóttir, B., Wettergreen, M., Torsetnes, S. B., Grøntvedt, G. R., Waterloo, K. K., Aarsland, D., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1399-2 · Cited by 274
Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer’s disease.
Puchades, M., Hansson, S. F., Nilsson, C. L., Andreasen, N., Blennow, K., & Davidsson, P. (2003) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.08.005 · Cited by 245
Self-citationWilson, M. R., Yerbury, J. J., & Poon, S. (2007) · Molecular BioSystems · doi:10.1039/b712728f · Cited by 142
Nilselid, A.-M., Davidsson, P., Nägga, K., Andreasen, N., Fredman, P., & Blennow, K. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.12.005 · Cited by 104
Self-citation
Metadata
- Authors
- Lidström, A.-M., Hesse, C., Rosengren, L., Fredman, P., Davidsson, P., & Blennow, K.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2001-09-30
- Volume
- 3
- Issue
- 5
- Pages
- 435-442
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2095677791
- Cited by
- 32
- References
- 10
- FWCI
- 0.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke. https://app.cochat.ai/papers/10.3233/jad-2001-3501
- The paper
- Lidström, A.-M., Hesse, C., Rosengren, L., Fredman, P., Davidsson, P., & Blennow, K. (2001). Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-2001-3501
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.